HEPATITIS B FOUNDATION AND
THE BARUCH S. BLUMBERG INSTITUTE
"Understanding HBsAg and subviral particles:
key players in chronic HBV infection and key targets in achieving functional cure of HBV"
Andrew Vaillant, Ph.D.
Dr. Vaillant has more than 15 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of Replicor’s NAP technology. He oversees all intellectual property, regulatory, manufacturing and research and development activities at Replicor. He also plays a key role in the design, conduct and oversight of clinical trials and oversees all clinical data analysis. He has authored numerous publications and patents on the use of NAPs in various infectious diseases. Dr. Vaillant also actively contributes in policy forums focused on accelerating the approval of novel antiviral therapies for HBV infection. He also serves on several working groups devoted to defining next generation approaches for assessing the antiviral efficacy and safety of novel combination therapies and to defining new approaches for determining functional control of HBV infection in clinical trials. He was a postdoctoral fellow at the Montreal Neurological Institute and holds a Ph.D. in Cell Biology from the University of Ottawa.
Andrew Vaillant, Ph.D., Chief Scientific Officer, Replicor Inc.